Ito, Hiroshi

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,669

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 758

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 386

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., et al. (2023) · Nature Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 215

Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial

Kosiborod, M. N., Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Jon Jensen, T., Rasmussen, S., Erlang Marstrand, P., Petrie, M. C., Shah, S. J., et al. (2024) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 104

Semaglutide and NT-proBNP in Obesity-Related HFpEF

Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Jensen, T. J., Einfeldt, M. N., Liisberg, K., et al. (2024) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 95

Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study

Nosaka, K., Miyoshi, T., Iwamoto, M., Kajiya, M., Okawa, K., Tsukuda, S., Yokohama, F., Sogo, M., Nishibe, T., Matsuo, N., et al. (2017) · International Journal of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 88